The invention concerns multimers developed from recombinant proteins analogues of MHC class I, characterised in that the proteins comprise at least an alteration in the zone of interaction of a heavy chain with the T-cell co-receptor CD8 leading to a reduction, even the suppression of the affinity of the interaction between the heavy chain and CD8. Said multimers forming complexes with antigenic peptides are useful for diagnostic and therapeutic purposes.
展开▼